Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31136155 | 0.87 | HPGD (0.57) | HPGDLMNAGAAKMT2AMEN1 | |
| SCHEMBL14230555 | 0.84 | MAPT (0.58) | HPGDLMNAGAAPOLBSMN1; SMN2 | |
| SCHEMBL11759644 | 0.83 | HDAC3 (0.60) | HPGDLMNAGAAKMT2AMEN1 | |
| SCHEMBL2010247 | 0.81 | SMN1; SMN2 (0.69) | HPGDGAAKMT2AMEN1POLB | |
| SCHEMBL4960066 | 0.81 | HPGD (0.62) | HPGDLMNAGAAPOLBSMN1; SMN2 | |
| SCHEMBL27713876 | 0.81 | POLB (0.59) | HPGDLMNAGAAKMT2AMEN1 | |
| SCHEMBL30259912 | 0.80 | NPSR1 (0.71) | LMNAGAAPOLBSMN1; SMN2MAPT | |
| SCHEMBL1063418 | 0.80 | NPSR1 (0.71) | LMNAGAAPOLBSMN1; SMN2MAPT | |
| SCHEMBL10172305 | 0.80 | SMN1; SMN2 (0.55) | HPGDLMNAGAAKMT2AMEN1 | |
| SCHEMBL24485241 | 0.79 | POLB (0.57) | HPGDLMNAGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | HPGD 314/4885LMNA 1413/4885GAA 57/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | HPGD 1458/4885LMNA 897/4885GAA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.